Zonisamide regulates basal ganglia transmission via astroglial kynurenine pathway
- PMID: 23973311
- DOI: 10.1016/j.neuropharm.2013.08.002
Zonisamide regulates basal ganglia transmission via astroglial kynurenine pathway
Abstract
To clarify the anti-parkinsonian mechanisms of action of zonisamide (ZNS), we determined the effects of ZNS on tripartite synaptic transmission associated with kynurenine (KYN) pathway (KP) in cultured astrocytes, and transmission in both direct and indirect pathways of basal ganglia using microdialysis. Interactions between cytokines [interferon-γ (IFNγ) and tumor-necrosis factor-α (TNFα)] and ZNS on astroglial releases of KP metabolites, KYN, kynurenic-acid (KYNA), xanthurenic-acid (XTRA), cinnabarinic-acid (CNBA) and quinolinic-acid (QUNA), were determined by extreme liquid-chromatography with mass-spectrometry. Interaction among metabotropic glutamate-receptor (mGluR), KP metabolites and ZNS on striato-nigral, striato-pallidal GABAergic and subthalamo-nigral glutamatergic transmission was examined by microdialysis with extreme liquid-chromatography fluorescence resonance-energy transfer detection. Acute and chronic ZNS administration increased astroglial release of KYN, KYNA, XTRA and CNBA, but not QUNA. Chronic IFNγ administration increased the release of KYN, KYNA, CNBA and QUNA, but had minimal inhibitory effect on XTRA release. Chronic TNFα administration increased CNBA and QUNA, but not KYN, KYNA or XTRA. ZNS inhibited IFNγ-induced elevation of KYN, KYNA and QUNA, but enhanced IFNγ-induced that of CNBA. TNFα-induced rises in CNBA and QUNA were inhibited by ZNS. ZNS inhibited striato-nigral GABAergic, striato-pallidal GABAergic and subthalamo-nigral glutamatergic transmission via activation of groups II and III mGluRs. ZNS enhanced astroglial release of endogenous agonists of group II mGluR, XTRA and group III mGluR, CNBA. Activated endogenous mGluR agonists inhibited transmission in direct and indirect pathways of basal ganglia. These mechanisms contribute to effectiveness and well tolerability of ZNS as an adjunct treatment for Parkinson's disease during l-DOPA monotherapy. This article is part of the Special Issue entitled 'The Synaptic Basis of Neurodegenerative Disorders'.
Keywords: Astrocyte; Cinnabarinic acid; Kynurenine pathway; Parkinson's disease; Xanthurenic acid; Zonisamide.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Similar articles
-
Effects of levetiracetam on astroglial release of kynurenine-pathway metabolites.Br J Pharmacol. 2018 Nov;175(22):4253-4265. doi: 10.1111/bph.14491. Epub 2018 Oct 6. Br J Pharmacol. 2018. PMID: 30153331 Free PMC article.
-
Carbamazepine Attenuates Astroglial L-Glutamate Release Induced by Pro-Inflammatory Cytokines via Chronically Activation of Adenosine A2A Receptor.Int J Mol Sci. 2019 Jul 30;20(15):3727. doi: 10.3390/ijms20153727. Int J Mol Sci. 2019. PMID: 31366130 Free PMC article.
-
Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway.Neuropharmacology. 2009 Sep;57(3):322-31. doi: 10.1016/j.neuropharm.2009.05.005. Epub 2009 May 29. Neuropharmacology. 2009. PMID: 19482038
-
[New prospects for antipsychotic treatment - the role of the kynurenine pathway].Psychiatr Pol. 2014 Nov-Dec;48(6):1167-77. doi: 10.12740/PP/25520. Psychiatr Pol. 2014. PMID: 25717486 Review. Polish.
-
Kynurenine pathway in Parkinson's disease-An update.eNeurologicalSci. 2020 Sep 10;21:100270. doi: 10.1016/j.ensci.2020.100270. eCollection 2020 Dec. eNeurologicalSci. 2020. PMID: 33134567 Free PMC article. Review.
Cited by
-
Upregulated Connexin 43 Induced by Loss-of-Functional S284L-Mutant α4 Subunit of Nicotinic ACh Receptor Contributes to Pathomechanisms of Autosomal Dominant Sleep-Related Hypermotor Epilepsy.Pharmaceuticals (Basel). 2020 Mar 29;13(4):58. doi: 10.3390/ph13040058. Pharmaceuticals (Basel). 2020. PMID: 32235384 Free PMC article.
-
Xanthurenic Acid Formation from 3-Hydroxykynurenine in the Mammalian Brain: Neurochemical Characterization and Physiological Effects.Neuroscience. 2017 Dec 26;367:85-97. doi: 10.1016/j.neuroscience.2017.10.006. Epub 2017 Oct 12. Neuroscience. 2017. PMID: 29031603 Free PMC article.
-
Clozapine Normalizes a Glutamatergic Transmission Abnormality Induced by an Impaired NMDA Receptor in the Thalamocortical Pathway via the Activation of a Group III Metabotropic Glutamate Receptor.Biomolecules. 2019 Jun 17;9(6):234. doi: 10.3390/biom9060234. Biomolecules. 2019. PMID: 31213006 Free PMC article.
-
Interaction between Mesocortical and Mesothalamic Catecholaminergic Transmissions Associated with NMDA Receptor in the Locus Coeruleus.Biomolecules. 2020 Jul 1;10(7):990. doi: 10.3390/biom10070990. Biomolecules. 2020. PMID: 32630356 Free PMC article.
-
Can rodent models elucidate the pathomechanisms of genetic epilepsy?Br J Pharmacol. 2022 Apr;179(8):1620-1639. doi: 10.1111/bph.15443. Epub 2021 May 12. Br J Pharmacol. 2022. PMID: 33689168 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources